Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) will present at the 7th Annual Wolfe Research Healthcare Conference on Monday, November 17, 2025. Management will take part in a Fireside Chat at 10:40 a.m. Eastern Time. A live audio webcast will be available on the company’s Investor Relations website and an archived edition will be posted later that day.
The audio webcast replay is expected to be available approximately 48 hours after the webcast. Media and investor contact emails are provided for follow-up.
Johnson & Johnson (NYSE:JNJ) reported Phase 1b/2 OrigAMI-4 results for subcutaneous amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) on Oct 19, 2025.
Key data: ORR 45% (38 efficacy-evaluable patients; 95% CI 29-62), median duration of response 7.2 months (95% CI 5.3-NE), tumor shrinkage in 82% of patients, and median PFS 6.8 months (95% CI 4.2-9.0). Safety across 86 patients showed common AEs: fatigue 31%, hypoalbuminemia 31%, stomatitis 23%; administration reactions 7%, discontinuation 2%.
Company is initiating Phase 3 OrigAMI-5 first-line study.
Johnson & Johnson (NYSE:JNJ) announced positive topline results from the Phase 3 MajesTEC-3 study of TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO versus investigator's choice (DPd or DVd) in relapsed/refractory multiple myeloma with one to three prior lines of therapy.
At almost three years follow-up the combination met the primary endpoint of progression-free survival (PFS) and the secondary endpoint of overall survival (OS) with statistically significant superiority; the IDMC recommended unblinding. Safety was consistent with known monotherapy profiles. Phase 2 MajesTEC-5 earlier showed a 100% overall response rate in transplant-eligible newly diagnosed patients.
Johnson & Johnson (NYSE: JNJ) announced a cash dividend of $1.30 per share for the fourth quarter of 2025. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025.
Johnson & Johnson (NYSE: JNJ) announced its intent to separate its Orthopaedics business into a standalone company to operate as DePuy Synthes. The company said the move aims to sharpen JNJ's focus on higher‑growth Innovative Medicine and MedTech areas and accelerate MedTech portfolio shifts toward higher‑margin markets. The Orthopaedics business reported ~$9.2 billion in sales for fiscal 2024 and serves a $50 billion+ global market. The company targets completion within 18–24 months and appointed Namal Nawana as Worldwide President of DePuy Synthes.
Johnson & Johnson (NYSE: JNJ) reported Q3 2025 sales of $23.99B, up 6.8% year-over-year, with operational growth of 5.4% and adjusted operational growth of 4.4%. GAAP diluted EPS was $2.12 and adjusted diluted EPS was $2.80 (+15.7% YoY). The company raised its full-year estimated reported sales guidance to a $93.7B midpoint and reaffirmed full-year adjusted EPS at a $10.85 midpoint while absorbing higher tax costs. Q3 product and pipeline highlights include U.S. approval of INLEXZO, subcutaneous TREMFYA approval in ulcerative colitis, a submission for icotrokinra, landmark overall survival data for RYBREVANT + LAZCLUZE, and long-term survival benefit for the Impella heart pump from DanGer Shock.
Johnson & Johnson (NYSE: JNJ) announced receipt of an unsolicited mini‑tender from Tutanota LLC to buy up to 500,000 shares at $145.00 per share. The offer equals about 0.0207% of JNJ outstanding shares as of the September 29, 2025 offer date and is conditioned on the closing price exceeding $145.00 on the last trading day before expiration.
Johnson & Johnson is not associated with the bidder, says the offer price is below recent market levels, warns the offer may be extended in successive 45–180 day periods, and recommends shareholders take no action and consult brokers or advisors. The offer is scheduled to expire at 5:00 p.m. ET on October 29, 2025 unless extended or terminated.
Johnson & Johnson (NYSE: JNJ) will present 17 abstracts at the 2025 ECNP Congress (October 11–14, Amsterdam) showcasing new clinical and real‑world data across major depressive disorder (MDD), treatment‑resistant depression (TRD) and schizophrenia.
Highlights include Phase 3 and post‑hoc analyses of adjunctive lumateperone (CAPLYTA) on sexual function and anhedonia, subgroup efficacy of adjunctive seltorexant versus quetiapine XR in EU/UK MDD with insomnia, and ESCAPE‑TRD analyses and French real‑world safety data for esketamine (SPRAVATO).
Johnson & Johnson (NYSE: JNJ) will present at the UBS Global Healthcare Conference on Tuesday, November 11, 2025. Management will take part in a Fireside Chat at 11:00 a.m. ET. A live audio webcast will be available on the company's investor relations site at www.investor.jnj.com, with an archived edition posted the same day and an audio replay available approximately 48 hours after the live event.
Johnson & Johnson (NYSE: JNJ) reported 48-week Phase 3 ASTRO results showing subcutaneous TREMFYA (guselkumab) achieved sustained clinical and endoscopic outcomes in adults with moderately to severely active ulcerative colitis.
At Week 48 TREMFYA 100 mg q8w and 200 mg q4w produced clinical remission 36.7% and 42.9%, endoscopic remission 25.9% and 26.4%, and symptomatic remission 47.5% and 53.6%, versus placebo 7.2%/5%/14.4% respectively. Results were consistent across biologic/JAK-naïve and refractory subgroups and safety matched the established profile. TREMFYA is the first IL-23 inhibitor with a fully subcutaneous regimen and has recent U.S. FDA SC induction approval for UC.